IBRX

ImmunityBio, Inc. Common Stock

7.96

USD

IBRX Earnings Reports

Positive Surprise Ratio

IBRX beat 23 of 41 last estimates.

56%

Next Report

Date of Next Report

May 11, 2026

Estimate for Q1 26 (Revenue/ EPS)

$44.03M

-$0.07

Implied change from Q4 25 (Revenue/ EPS)

+15.01%

+16.67%

Implied change from Q1 25 (Revenue/ EPS)

+166.59%

-53.33%

ImmunityBio, Inc. Common Stock earnings per share and revenue

On Feb 23, 2026, IBRX reported earnings of -0.06 USD per share (EPS) for Q4 25, beating the estimate of -0.09 USD, resulting in a 37.43% surprise. Revenue reached 38.28 million, compared to an expected 37.76 million, with a 1.39% difference. The market reacted with a +12.99% price change (close before vs. close after earnings).

Looking ahead to Q1 26, 4 analysts forecast an EPS of -0.07 USD, with revenue projected to reach 44.03 million USD, implying an increase of 16.67% EPS, and increase of 15.01% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

Celcuity Inc. Common Stock

Report Date

Mar 25, 2026 For Q4 25

Estimate

-$1.06

Actual

-$0.97

Surprise

+8.72%

Precigen, Inc. Common Stock

Report Date

Mar 25, 2026 For Q4 25

Estimate

-$0.08

Actual

-$0.01

Surprise

+88.24%

Absci Corporation Common Stock

Report Date

Mar 24, 2026 For Q4 25

Estimate

-$0.19

Actual

-$0.23

Surprise

-16.04%

Candel Therapeutics, Inc. Common Stock

Report Date

Mar 26, 2026 For Q4 25

Estimate

-$0.25

Actual

-$0.54

Surprise

-115.31%

LENZ Therapeutics, Inc. Common Stock

Report Date

Mar 24, 2026 For Q4 25

Estimate

-$0.99

Actual

-$1.15

Surprise

-17.10%

Fennec Pharmaceuticals Inc. Common Stock

Report Date

Mar 24, 2026 For Q4 25

Estimate

$0.03

Actual

-$0.11

Surprise

-408.12%

Equillium, Inc. Common Stock

Report Date

Mar 25, 2026 For Q4 25

Estimate

-$0.06

Actual

-$0.04

Surprise

+35.28%

MaxCyte, Inc. Common Stock

Report Date

Mar 24, 2026 For Q4 25

Estimate

-$0.08

Actual

-$0.06

Surprise

+26.47%

TELA Bio, Inc. Common Stock

Report Date

Mar 24, 2026 For Q4 25

Estimate

-$0.18

Actual

-$0.16

Surprise

+14.12%

Dyadic International, Inc.

Report Date

Mar 25, 2026 For Q4 25

Estimate

-$0.04

Actual

-$0.06

Surprise

-30.72%

FAQ

What were ImmunityBio, Inc. Common Stock's earnings and revenue for the latest quarter Q4 2025?

For Q4 2025, ImmunityBio, Inc. Common Stock reported EPS of -$0.06, beating estimates by 37.43%, and revenue of $38.28M, 1.39% above expectations.

How did the market react to ImmunityBio, Inc. Common Stock's Q4 2025 earnings?

The stock price moved up 12.99%, changed from $8.70 before the earnings release to $9.83 the day after.

When is ImmunityBio, Inc. Common Stock expected to report next?

The next earning report is scheduled for May 11, 2026.

What are the forecasts for ImmunityBio, Inc. Common Stock's next earnings report?

Based on 4 analysts, ImmunityBio, Inc. Common Stock is expected to report EPS of -$0.07 and revenue of $44.03M for Q1 2026.

Which companies are reporting earnings today?

Check FXEmpire's Earnings Calendar for today's list of reporting companies.